10 Best Railroad Stocks To Watch Right Now

On this day in economic and business history...

Jay Cooke & Company failed on Sept. 18, 1873, triggering a financial panic that soon plunged the United States into a "Great Depression." This depression remained the national benchmark for economic woe for decades before the 1930s took over that term.

The basic backstory of this failure should be familiar: A major financier invests heavily into a speculative bubble -- in this case, railroads -- and uses excessive leverage to maximize returns while everything moves in the right direction. Then the bubble pops, and the financier is left without the means to pay back creditors. A sudden lack of liquidity cascades through the financial system as everyone rushes to withdraw money, only to find that in many cases their profits or their savings exist only as notations in their bank's records. Everybody panic!

The particulars of 1873, however, make it worth a closer investigation.

The boom leading up to the 1873 panic was the first true "tech" bubble, driven entirely by the excitement surrounding a promising new industry, rather than by real-estate speculation, trade imbalances, or financial shenanigans. (A boom preceding the Panic of 1857 also involved railroads, but this earlier bubble was driven in large part by Midwestern land speculation.)

5 Best Healthcare Equipment Stocks To Buy For 2015: Telular Corporation(WRLS)

Telular Corporation designs, develops, and distributes products and services that utilize wireless networks to provide data and voice connectivity among people and machines primarily in the United States and internationally. It provides machine-to-machine and event monitoring services, including Telguard that comprises a specialized terminal unit, which interfaces with commercial security control panels and communicates with event processing servers to provide real-time transport of alarm signals from residential and commercial locations to an alarm company?s central monitoring station; and TankLink solution that combines a cellular communicator, wireless data services, and a Web-based application into a single offering, which allows end-users to monitor the product level in a given tank vessel. The company also offers fixed cellular terminals for voice, fax, and Internet access over the wireless networks. It sells its products to security equipment distributors, cellular carriers, and value added resellers. The company was founded in 1986 and is headquartered in Chicago, Illinois.

Advisors' Opinion:

• [By Eric Volkman]

  Telular (NASDAQ: WRLS  ) will most likely soon be an asset belonging to another company. It has entered into an agreement to be bought by private equity firm Avista Capital Partners for total consideration of $253 million. This consists of $12.61 per share in cash and roughly $18.5 million in assumed debt.

10 Best Railroad Stocks To Watch Right Now: ML Capital Group Inc (MLCG)

ML CAPITAL GROUP. INC., incorporated on September 27, 2009, is an exploration-stage company. The Company was engaged in conducting assistance with financing needs of MicroCap corporations.

The Company is focused on research on line, attend trade shows and contact its associates in several industries. As of September 7, 2011, the Company had not generated revenue.

Advisors' Opinion:

• [By Peter Graham]

  Small cap marijuana stocks IMD Companies Inc (OTCMKTS: ICBU), Tauriga Sciences Inc (OTCMKTS: TAUG), ML Capital Group Inc (OTCBB: MLCG) and Lexaria Corp (OTCMKTS: LXRP) are aiming to give investors a high with their latest news. However, only one of these small cap marijuana stocks appears to be the subject of minor paid promotion or investor relations type of activities. So will investors and traders alike get a high off of these small caps? Here is a quick reality check:

10 Best Railroad Stocks To Watch Right Now: Dejour Energy Inc (DEJ)

Dejour Energy Inc. is engaged in the business of acquiring, exploring and developing energy projects with a focus on oil and gas exploration in Canada and the United States. The Company holds approximately 113,000 net acres of oil and gas leases in the Peace River Arch of northwestern British Columbia and northeastern Alberta, Canada and the Piceance, Paradox and Uinta Basins in the United States Rocky Mountains. The Company has 71.43% working interest in this 3,014 acre (gross) project located south of Roan Creek. The Company also has 71.43% working interest in this 18,000 acre (gross) project located north of the Rangely Field, is prospective for oil in the Lower Mancos (Niobrara), Dakota, Morrison and Phosphoria formations. Advisors' Opinion:

• [By CRWE]

  Vancouver, BC, Dec. 16, 2013 — (CRWE Press Release) — Dejour Energy Inc. (NYSE MKT:DEJ) (TSX:DEJ), an independent oil and natural gas exploration and production company operating in North America’s Piceance Basin and Peace River Arch regions, today announces that it has signed a Letter of Intent to create a strategic joint venture partnership with a private Singapore based energy company (��ECO�� to develop the company�� Colorado oil and gas assets.

  Upon completion of due diligence, legal documentation and requisite approvals expected prior to January 31, 2014, SECO will invest an initial sum of up to $27.5mm in 2014 and 2015 to earn an 85% share in Dejour�� interests in its Colorado properties, primarily Kokopelli, subject to certain interest claw backs available to Dejour. Following this capital investment by SECO, the partners will continue to judiciously develop the reserves on a pro rata basis.

  The terms of the agreement include a capital injection to Dejour of approximately US$ 4.5mm, including cash and assumption of certain liability agreements on outstanding debt and the 100% development funding of an initial $10.5mm in capital expenditures in 2014 with a further $12mm in 2015, targeting Kokopelli, subject to certain provisions. Additionally, SECO will assume 85% of the ongoing overhead of Dejour�� U.S. operations and joint project management during the initial period. SECO will also share responsibility to maintain the other Dejour U.S. leases in good standing on a pro rata ownership basis or return them to Dejour in a timely fashion. Dejour will remain the operator of record.

  ��ECO shares Dejour�� value proposition relating to the company�� U.S. E&P portfolio. This partnership will bring many strategic advantages to Dejour: minimizing capital requirement in the short term, bolstering the company�� balance sheet and long term US cash flow, the provision of flexibility for Dejour to pursue new

10 Best Railroad Stocks To Watch Right Now: Rockwell Automation Inc.(ROK)

Rockwell Automation, Inc. provides industrial automation power, control, and information solutions. It operates in two segments, Architecture and Software, and Control Products and Solutions. The Architecture and Software segment offers control platforms that perform multiple control disciplines and monitoring of applications, including discrete, batch and continuous process, drives control, motion control, and machine safety control; and products comprising controllers, electronic operator interface devices, electronic input/output devices, communication and networking products, and industrial computers. This segment also offers software products, such as configuration and visualization software used to operate and supervise control platforms, advanced process control software, and manufacturing execution software to enhance manufacturing productivity and meet regulatory requirements; and rotary and linear motion control products, and sensors and machine safety components . The Control Products and Solutions segment provides low and medium voltage electro-mechanical and electronic motor starters, motor and circuit protection devices, AC/DC variable frequency drives, push buttons, signaling devices, termination and protection devices, relays and timers, and condition sensors; and packaged solutions, such as configured drives and motor control centers to automation and information solutions, as well as life-cycle support services. The company sells its products, solutions, and services primarily under the Rockwell Automation, Allen-Bradley, A-B, and Rockwell Software brand names to the food and beverage, transportation, oil and gas, metals, mining, home and personal care, pulp and paper, and life sciences markets through independent distributors and direct sales force in the United States, Canada, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. Rockwell Automation, Inc. was founded in 1928 and is headquartered in Milwaukee , Wisconsin.

Advisors' Opinion:

• [By Blake Bos]

  In the following video, Fool consumer-goods/industrials analyst Blake Bos breaks down Aviation Week's top aerospace and defense picks by annual revenue. His discussion includes Cubic (NYSE: CUB  ) , Rockwell Automation (NYSE: ROK  ) , Exelis (NYSE: XLS  ) , Boeing (NYSE: BA  ) , and Lockheed Martin (NYSE: LMT  ) .

10 Best Railroad Stocks To Watch Right Now: Echo Therapeutics Inc (ECTE)

Echo Therapeutics, Inc. (Echo), incorporated on September 10, 2007, is a transdermal medical device company. The Company is developing Prelude SkinPrep System (Prelude) as a technology to allow for painless and skin permeation that enable both analyte extraction and needle-free drug delivery. The Company is developing its Symphony CGM System (Symphony) as a non-invasive, wireless continuous glucose monitoring (CGM) system for use in hospital critical care units and for people with diabetes. The Prelude SkinPrep System (Prelude), a component of its Symphony CGM System, allows for skin permeation that enables extraction of analytes such as glucose. Prelude�� platform skin preparation technology also allows for needle-free, transdermal drug delivery.

Symphony CGM System

The Symphony CGM System incorporates a Prelude skin preparation device, transdermal sensor, wireless transmitter and data display monitor. When the electro-chemical glucose sensor is placed on the prepared site, it uses glucose oxidase to generate a continuous current that is proportional to the concentration of blood glucose in the vessels beneath the epidermis. The signals are then wirelessly transmitted to a remote monitor. The monitor, calibrated periodically with a reference blood glucose measurement, converts the data to a glucose measurement based on the reference value. The monitor displays glucose readings and also contains customizable early-warning alarms for hypo- or hyperglycemia.

Prelude SkinPrep System

The Company is developing Prelude as a transdermal skin preparation device for Symphony to improve the access to the interstitial fluids and the flow of molecules across the protective membrane of the stratum corneum, the outmost protective layer of the skin. Prelude incorporates the Company's skin abrasion control technology into a hand-held device used to prepare a small area of the skin. The non-invasive sensor is applied to this prepared area in order to measure the in! terstitial glucose levels.

Specialty Pharmaceuticals

The Company�� specialty pharmaceuticals pipeline is based on itsAzone transdermal drug reformulation technology. AzoneTS is a nontoxic, nonirritating skin penetration that is intended to enable topical application of food and drug administration (FDA) -approved drugs, including pharmaceutical products that previously could only be administered systemically. Its advanced drug candidate is Durhalieve, an AzoneTS formulation of triamcinolone acetonide, medium potency corticosteroid approved by the FDA for treatment of corticosteroid-responsive dermatoses. AzoneTS increases lipid membrane fluidity in the stratum corneum layer of the skin, thereby decreasing resistance to topically applied therapeutics.

The Company competes with Roche, Johnson & Johnson, Bayer, Abbott Laboratories , DexCom, Inc., Medtronic, Inc., Edwards Lifesciences Corporation, Optiscan Biomedical Corp., Medtronic, Glysure, Glumetrics Inc., Maquet and A. Menarini Diagnostics S.r.l.

Advisors' Opinion:

• [By Bryan Murphy]

  Truth be told, Echo Therapeutics Inc. (NASDAQ:ECTE) doesn't look like a particularly impressive stock right now. At $2.92 per share, ECTE is just trading right around where it was a few days ago, not to mention a few weeks ago. And, without any real "news" from the company in months, it's tough to think the market's going to be getting excited about the stock anytime soon. When you take a closer look at Echo Therapeutics though, a few subtle-but-compelling clues start to appear.

• [By Roberto Pedone]

  Another under-$10 health care player that's quickly moving within range of triggering a major breakout trade is Echo Therapeutics (ECTE), which is a transdermal medical device company with skin permeation technology. This stock has been destroyed by the bears so far in 2013, with shares off huge by 70%.

  If you take a look at the chart for Echo Therapeutics, you'll notice that this stock has been uptrending strong for the last month, with shares moving higher from its low of $2.14 to its intraday high of $3.06 a share. During that uptrend, shares of ECTE have been consistently making higher lows and higher highs, which is bullish technical price action. That move has pushed shares of ECTE back above its 50-day moving average at $2.65 a share, and it's just starting to push ECTE into breakout territory, since the stock has cleared some key near-term overhead resistance levels at $2.98 to $2.99 a share. That move is quickly pushing shares of ECTE within range of triggering an even bigger breakout trade.

  Market players should now look for long-biased trades in ECTE if it manages to break out above some major near-term overhead resistance at $3.30 a share with high volume. Look for a sustained move or close above that level with volume that registers near or above its three-month average volume of 211,103 shares. If that breakout triggers soon, then ECTE will set up to re-test or possibly take out its next major overhead resistance levels at $4 to $4.50 a share, or possibly even $5 to $6 a share.

  Traders can look to buy ECTE off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $2.65 a share, or right below more near-term support at $2.50 a share. One can also buy ECTE off strength once it clears $3.30 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

10 Best Railroad Stocks To Watch Right Now: Aberdeen Australia Equity Fund Inc (IAF)

Aberdeen Australia Equity Fund, Inc. (the Fund) is a closed-end, non-diversified management investment company. The Fund�� principal investment objective is long-term capital appreciation through investment primarily in equity securities of Australian companies listed on the Australian Stock Exchange Limited. Its secondary objective is current income, which is expected to be derived primarily from dividends and interest on Australian corporate and governmental securities. The Fund invests at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in equity securities, consisting of common stock, preferred stock and convertible stock, of companies tied economically to Australia (each an Australian Company), and at least 65% of its total assets in equity securities, consisting of common stock, preferred stock and convertible stock, listed on the Australian Stock Exchange Limited (ASX). Advisors' Opinion:

• [By Dividends4Life]

  According to a Gabelli Funds report, managed distribution policies offer several advantages, including:1. Lower difference between the fund�� market price and its NAV per share.2. Provides support during periods when the stock market is in a decline.3. Provides a measurable performance target for the investment adviser.Below are several high-yield funds from CEFA that have a managed distribution policy (yields as of December 16):Aberdeen Australia Eqty (IAF)- Distribution Yield: 10.4%- Income Yield: 3.46%Bexil Advisers LLC� (DNI)- Distribution Yield: 11.1%- Income Yield: 3.56%BlackRock En Capital&Inc (CII)- Distribution Yield: 8.78%- Income Yield: 2.34%Cornerstone Strat Value (CLM)- Distribution Yield: 18.77%- Income Yield: 1.83%Cornerstone Total Return (CRF)- Distribution Yield: 19.10%- Income Yield: 0.85%Delaware Inv Div & Inc (DDF)- Distribution Yield: 6.70%- Income Yield: 5.26%Gabelli Equity Trust (GAB)- Distribution Yield: 7.58%- Income Yield: 1.54%Gabelli Utility Trust (GUT)- Distribution Yield: 9.45%- Income Yield: 2.84%MFS Special Value Trust (MFV)- Distribution Yield: 9.60%- Income Yield: 5.73%Nuveen Tx-Adv TR Strat (JTA)- Distribution Yield: 6.70%- Income Yield: 3.12%TCW Strategic Income (TSI)- Distribution Yield: 10.54%- Income Yield: 7.88%Zweig Total Return (ZTR)- Distribution Yield: 7.27%- Income Yield: 1.95%As noted in the Gabelli report, a managed distribution policy may create confusion regarding the true current yield since the reported yield includes the return of capital portion. You can see the disparity above between the income yield and the distribution (reported) yield.If you are looking for a sustainable and growing dividend, you may want to consider some blue-chip dividend stocks such as these with a Free Cash Flow Payout less than 50%, 50+ years of consecutive dividend increases and a 2%+ yield:3M Co. (MMM) is a diversified global company provides enhanced product functionality in electronics, health care, industrial, consumer

10 Best Railroad Stocks To Watch Right Now: Biota Pharmaceuticals Inc (BOTA)

Biota Pharmaceuticals, Inc., formerly Nabi Biopharmaceuticals, incorporated on March 14, 1969, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza. Biota developed the neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. The Company�� researches include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir, is approved for marketing in Japan.

The Company�� products include Zanamivir, Inavi, Phoslyra, BioStar OIA FLU and BioStar OIA FLU A/B. Zanamivir is a neuraminidase inhibitor for the treatment and prophylaxis of influenza marketed as Relenza by GlaxoSmithKline. Inavi (laninamivir) is a neuraminidase inhibitor marketed by Daiichi Sankyo in Japan. Phoslyra is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD). BioStar OIA FLU and BioStar OIA FLU A/B are influenza diagnostic tests, which are marketed by Inverness Medical as part of their BioStar product range.

Relenza is delivered directly to the primary site of infection on the lungs, using a Disk Inhaler device. Relenza is approved in over 50 countries for the treatment of influenza, including in the United States, the European Union, Japan and Australia. Relenza is also approved for use as a preventative (prophylactic) treatment against influenza. Inavir is approved for sale in Japan for the treatment of influenza in adults and children. Daiichi Sankyo has applied to sell Inavir in Japan for the prevention of influenza.

PhosLo and Phoslyra are different dose forms of calcium acetate; a phosphate binder approved in multiple countries for the control of hyperphosphatemia (high serum phosphate) in patients with end stage renal disease (ESRD). PhosLo and Pho! slyra were sold to Fresnius Medical Care. Biota, together with its Japanese based partner, Daiichi Sankyo, have developed an inhaled antiviral compounds for influenza, called long acting inhaled neuraminidase inhibitors (LANI). Biota's human rhinovirus (HRV) drug for the prevention and treatment of the causes of the common cold, BTA798, has completed Phase I, Phase IIa and Phase IIb clinical trials.

Advisors' Opinion:

• [By gurujx]

  Biota Pharmaceuticals Inc (BOTA) Reached the 3-year Low of $2.42

  The prices of Biota Pharmaceuticals Inc (BOTA) shares have declined to close to the 3-year low of $2.42, which is 93.3% off the 3-year high of $34.92.